NORMAX STORY
Normax® mRNA Vaccine R&D and CDMO Vax Factories for Transformative Social Impact
Normax. Loving Life.
WEBSITE for Normax Biomed Limited (NRMX)
WEBSITE for Normax Biomed Limited (NRMX)
Normax Extreme Social Impact (ESI) Blog
Normax Extreme Social Impact (ESI) Blog
VAST PROBLEM: PATHOGENS & PANDEMICS
FACT: EXTREME COST of COVID-19, PATHOGENS & PANDEMIC RISK
FACT: EXTREME COST of COVID-19, PATHOGENS & PANDEMIC RISK
WHO. 04 JAN 2023: "XBB.1.5 Most Transmissible Subvariant Yet."
WHO. 04 JAN 2023: "XBB.1.5 Most Transmissible Subvariant Yet."
BIOSECURITY: Inevitable Evolution of COVID and New Pathogens
BIOSECURITY: Inevitable Evolution of COVID and New Pathogens
EVERY 20 SECONDS in 2021... Somebody DIED of Tuberculosis (WHO)
EVERY 20 SECONDS in 2021... Somebody DIED of Tuberculosis (WHO)
NORMAX MISSION (1 Minute)
The MISSION of Normax (1:00)
Vimeo
The MISSION of Normax (1:00)
NEWS, ESG POST, TWEETS, PRESS ROOM
Normax IN-THE-NEWS
Normax IN-THE-NEWS
Normax PRESS ROOM
Normax PRESS ROOM
Normax on TWITTER
Normax on TWITTER
Normax on THE ROAD TO IRELAND with Pharma's Almanac (4:26)
Vimeo
Normax on THE ROAD TO IRELAND with Pharma's Almanac (4:26)
NORMAX SUMMARY, FAQ, PARTNERS
Normax SUMMARY
Normax SUMMARY
Normax FAQ
Normax FAQ
Normax at VALIDATE NETWORK
Normax at VALIDATE NETWORK
Peter Jensen, VALIDATE Network Affiliate, Norvax UK Ltd
mRNA UCV Consortium by Normax
mRNA UCV Consortium by Normax
NRMX ESG: mRNA VACCINES SAVE LIVES
Normax SOCIAL VALUE (ESG) for Stakeholders and Investors
Normax SOCIAL VALUE (ESG) for Stakeholders and Investors
PURPOSE, CULTURE & VALUES of Normax
PURPOSE, CULTURE & VALUES of Normax
LOW-COST mRNA VACCINES for COVID, TB, HIV... by Normax
LOW-COST mRNA VACCINES for COVID, TB, HIV... by Normax
VACCINE EQUITY. mRNA Vaccines by Normax. Save a Life for $4.00
VACCINE EQUITY. mRNA Vaccines by Normax. Save a Life for $4.00
EDITORIAL. European Pharmaceutical Manufacturer. The time for mRNA vaccine equality across the globe by Peter Jensen
EDITORIAL. European Pharmaceutical Manufacturer. The time for mRNA vaccine equality across the globe by Peter Jensen
NO PANDEMICS by Normax. PATHOGENS and PANDEMICS. A Deadly Cost and Risk For All.
NO PANDEMICS by Normax. PATHOGENS and PANDEMICS. A Deadly Cost and Risk For All.
Outbreaks are inevitable. Pandemics are not. Our Mission Our mission is to participate as a strategic partner in the global ecosystem for transformative research, development and manufacture of safe and effective mRNA vaccines for
GOAL 2050 by Normax. End transmission of TB and HIV by 2050.
GOAL 2050 by Normax. End transmission of TB and HIV by 2050.
EASY ANALYSIS: MARKET DATA
THE LANCET. 19.8 million deaths from COVID-19 averted during the first year of COVID-19 vaccination
THE LANCET. 19.8 million deaths from COVID-19 averted during the first year of COVID-19 vaccination
REPORT. COVID-19 Vaccination program in U.S. saved 3.2 million lives and U.S. $1.15 trillion in 2 years
REPORT. COVID-19 Vaccination program in U.S. saved 3.2 million lives and U.S. $1.15 trillion in 2 years
QUICK FACTS. mRNA Vaccine Technology & mRNA in Nature
QUICK FACTS. mRNA Vaccine Technology & mRNA in Nature
OPEN ACCESS DATA. Scientific Reference & Review Digest
OPEN ACCESS DATA. Scientific Reference & Review Digest
MARKET REPORTS. Long-Term Market Outlook for mRNA Vaccines and Therapeutics and SARS-CoV-2 Vaccines for Endemic COVID-19
MARKET REPORTS. Long-Term Market Outlook for mRNA Vaccines and Therapeutics and SARS-CoV-2 Vaccines for Endemic COVID-19
MARKET DATA. Leading mRNA Biomedical & Biotech Companies
MARKET DATA. Leading mRNA Biomedical & Biotech Companies
MARKET DATA. $110-$130 per Covid Vaccine by Moderna & Pfizer
MARKET DATA. $110-$130 per Covid Vaccine by Moderna & Pfizer
MARKET DATA. Covid-19 mRNA Vaccines Lead Drug Sales 2021/22
MARKET DATA. Covid-19 mRNA Vaccines Lead Drug Sales 2021/22
BNTX Q3 2022 EXAMPLE: "€13.4 billion cash and cash equivalents plus total trade receivables of €7.3 billion"
BNTX Q3 2022 EXAMPLE: "€13.4 billion cash and cash equivalents plus total trade receivables of €7.3 billion"
QUICK STUDY: PROFESSIONAL INVESTORS
€300,000,000 CAPITAL COMMITMENT secured by Normax
€300,000,000 CAPITAL COMMITMENT secured by Normax
Normax Story FOR INVESTORS in a few minutes...
Normax Story FOR INVESTORS in a few minutes...
Linkedin: Peter A. Jensen, CEO & Chairman, Normax Biomed Ltd.
Linkedin: Peter A. Jensen, CEO & Chairman, Normax Biomed Ltd.
CONTACT US
View on mobile
Explore other Linktrees
Raedio
@raedio
Alyson Stoner
@alysonstoner
Lindsey Arnold
@Lindsarnold
Halley Kate
@halleykmcg
goodnoticingspod
@goodnoticingspod
jimgaffigan
@jimgaffigan
Mykel
@dont.chase.your.d
Boze vs The World
@bozevstheworld
ericclapton
@ericclapton
Charli Andrea
@charliandrea
previous
next
Discover more
See all
@psistefanygreice
@Diana_bor
@Autoitaliawebromanord
@onlyhr22
@_thefitfather_
@Jolijolan
@iammelissapeters
@reginaldgrey
@TheBoardroomBristol
@kezservices.co.uk
@shesaidmine
@jesusmanzano
@msbtechus
@johanacastillo
@charlieschnurrmusic
@indsocunsw
@djanuragahouseandvilla
@Ceces_Crafty_Creations
@Kingflex_Sales2
@AllFitnessrd
@bardoleo
@AnastaciaHernandez
@heis_saidimbano
@jocolvinrealtor
@sunspirit7
@Yoginpao
@mrssager
@all_about_ud.dep
@agam.imigrasi
@psicoestefaniamastandrea
@rumahhijabhumaira
@lioraastudio
@ventas_pieldeoro
@belusoqueff
@brandrive
@luna.streetcoffee
@Oreo_Skittles19
@nashbrowin
@adhmcreative
@NURIS_MARA
@thecoopscoop
@fio_mostarda
@ahmeed.coach
@KilmerDrama
@tammyrothforgottencoast